Lilly, Anthem Singing Same Tune On Value-Based Pricing, Communication Policy
This article was originally published in RPM Report
Executive Summary
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
You may also be interested in...
HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.
Value-Based Contracts: Relief From Regulatory Barriers In Sight?
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.